Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Reslizumab (Asthma): Nutzenbewertung gemäß § 35a SGB V; Dossierbewertung; Auftrag A17-02. [Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 505. 2017 Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Asthma; Humans; Pulmonary Eosinophilia Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte@iqwig.de AccessionNumber 32017000257 Date abstract record published 13/06/2017 |